GLGuangwei Li

Guangwei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangwei Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness of Different Intervention Modes in Lifestyle Intervention for the Prevention of Type 2 Diabetes and the Reversion to Normoglycemia in Adults With Prediabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Yachen Wang, Xin Chai, Yueqing Wang, Xuejun Yin, Xinying Huang, Qiuhong Gong, Juan Zhang, Ruitai Shao, Guangwei Li

    Background: Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation. Despite this, there remains a significant gap in understanding the effectiveness of digital health for individuals with prediabetes, particularly in reducing T2DM incidence and reverting to normoglycemia. Objective: This study aimed to assess the effectiveness of different intervention modes of digital health, face-to-face, and blended interventions, particularly the benefits of digital health intervention, in reducing T2DM incidence and facilitating the reversion to normoglycemia in adults with prediabetes compared to the usual care. Methods: We conducted a comprehensive search in 9 electronic databases, namely MEDLINE, Embase, ACP Journal Club, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, Cochrane Methodology Register, Health Technology Assessment, and NHS Economic Evaluation Database through Ovid, from the inception to October 2024. This review included randomized controlled trials (RCTs) that studied the effectiveness of lifestyle interventions in adults with prediabetes. The overall intervention effect was synthesized using a random-effects model. The I² statistic was used to assess heterogeneity across the RCTs. We performed a subgroup analysis to explore the effectiveness of digital health, face-to-face, and blended interventions compared with the control group, which received usual care. Results: From an initial 7868 records retrieved from 9 databases, we identified 54 articles from 31 RCTs. Our analysis showed that face-to-face interventions demonstrated a significant 46% risk reduction in T2DM incidence (risk ratio [RR] 0.54, 95% CI 0.47-0.63; I²=43%; P<.001), and a 46% increase in the reversion to normoglycemia (RR 1.46, 95% CI 1.11-1.91; I²=82%; P=.006), when compared with the control group. On the other hand, digital health interventions, compared with the control group, were associated with a 12% risk reduction in T2DM incidence (RR 0.88, 95% CI 0.77-1.01; I²=0.6%; P=.06). Moreover, the blended interventions combining digital and face-to-face interventions suggested a 37% risk reduction in T2DM incidence (RR 0.63, 95% CI 0.49-0.81;I²<0.01%; P<.001) and an 87% increase in the reversion to normoglycemia (RR 1.87, 95% CI 1.30-2.69; I²=23%; P=.001). However, no significant effect on the reversal of prediabetes to normoglycemia was observed from the digital health interventions. Conclusions: Face-to-face interventions have consistently demonstrated promising effectiveness in both reductions in T2DM incidence and reversion to normoglycemia in adults with prediabetes. However, the effectiveness of digital health interventions in these areas has not been sufficiently proven. Given these results, further research is required to provide more definitive evidence of digital health and blended interventions in T2DM prevention in the future. Trial Registration: PROSPERO CRD42023414313; https://tinyurl.com/55ac4j4n


  • Open Access

    Effectiveness of Different Intervention Modes in Lifestyle Intervention for the Prevention of Type 2 Diabetes and the Reversion to Normoglycemia in Adults With Prediabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials (Preprint)

    by Yachen Wang, Xin Chai, Yueqing Wang, Xuejun Yin, Xinying Huang, Qiuhong Gong, Juan Zhang, Ruitai Shao, Guangwei Li

    BACKGROUND Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation. Despite this, there remains a significant gap in understanding the effectiveness of digital health for individuals with prediabetes, particularly in reducing T2DM incidence and reverting to normoglycemia. OBJECTIVE This study aimed to assess the effectiveness of different intervention modes of digital health, face-to-face, and blended interventions, particularly the benefits of digital health intervention, in reducing T2DM incidence and facilitating the reversion to normoglycemia in adults with prediabetes compared to the usual care. METHODS We conducted a comprehensive search in 9 electronic databases, namely MEDLINE, Embase, ACP Journal Club, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, Cochrane Methodology Register, Health Technology Assessment, and NHS Economic Evaluation Database through Ovid, from the inception to October 2024. This review included randomized controlled trials (RCTs) that studied the effectiveness of lifestyle interventions in adults with prediabetes. The overall intervention effect was synthesized using a random-effects model. The I² statistic was used to assess heterogeneity across the RCTs. We performed a subgroup analysis to explore the effectiveness of digital health, face-to-face, and blended interventions compared with the control group, which received usual care. RESULTS From an initial 7868 records retrieved from 9 databases, we identified 54 articles from 31 RCTs. Our analysis showed that face-to-face interventions demonstrated a significant 46% risk reduction in T2DM incidence (risk ratio [RR] 0.54, 95% CI 0.47-0.63; I²=43%; P<.001), and a 46% increase in the reversion to normoglycemia (RR 1.46, 95% CI 1.11-1.91; I²=82%; P=.006), when compared with the control group. On the other hand, digital health interventions, compared with the control group, were associated with a 12% risk reduction in T2DM incidence (RR 0.88, 95% CI 0.77-1.01; I²=0.6%; P=.06). Moreover, the blended interventions combining digital and face-to-face interventions suggested a 37% risk reduction in T2DM incidence (RR 0.63, 95% CI 0.49-0.81;I²<0.01%; P<.001) and an 87% increase in the reversion to normoglycemia (RR 1.87, 95% CI 1.30-2.69; I²=23%; P=.001). However, no significant effect on the reversal of prediabetes to normoglycemia was observed from the digital health interventions. CONCLUSIONS Face-to-face interventions have consistently demonstrated promising effectiveness in both reductions in T2DM incidence and reversion to normoglycemia in adults with prediabetes. However, the effectiveness of digital health interventions in these areas has not been sufficiently proven. Given these results, further research is required to provide more definitive evidence of digital health and blended interventions in T2DM prevention in the future. CLINICALTRIAL PROSPERO CRD42023414313; https://tinyurl.com/55ac4j4n

  • Breakthrough in diabetes and cardiovascular disease prevention: a 30-year study of diabetes prevention in Daqing

    by YaLi AN, JinPing WANG, YanYan CHEN, GuangWei LI, QiuHong GONG, XiaoXia SHEN

    Type 2 diabetes represents an immense and growing public health challenge worldwide for its extremely high risk of blindness, renal failure, myocardial infarction and stroke. In the 1980s, it was unclear whether diabetes is preventable. Up to 2000, it remained unclear whether diabetes can be delayed over a long period by active lifestyle intervention and whether the benefits of diabetes prevention can extend to the prevention of diabetic vascular complications and the reduction of mortality. The Diabetes Prevention Study in Daqing is one of the first studies to answer these questions. The major lessons we learnt from this study are as follows. Over 23 years, 56% people with newly diagnosed diabetes died, of whom 50% died of cardiovascular disease (CVD) with a 10-year less life expectancy. More than 90% people with impaired glucose tolerance (IGT) experienced diabetes, 33% of whom died and 44% had at least one CVD event in the subsequent 20 years. The all-cause death and CVD events over 20 years’ follow-up period in this IGT population mainly occurred after the progression to diabetes. A group-based lifestyle interventions over 6-year period had long-term effects on prevention of diabetes beyond the period of 6-year active intervention. Benefits of the intervention significantly reduced severe diabetes retinopathy and extended to a favorable reduction of CVD and all-cause mortality. This study has an important impact on the worldwide prevention of diabetes and its vascular complications.


  • Influence of improvement or worsening of glucose tolerance on risk of stroke in persons with impaired glucose tolerance

    by Xiaoxia Shen, Ping Zhang, Jinping Wang, Yali An, Edward W Gregg, Bo Zhang, Hui Li, Qiuhong Gong, Yanyan Chen, Ying Shuai, et al.

    We sought to determine the effect of regression to normal glucose tolerance (NGT) or progression to diabetes in early years of impaired glucose tolerance (IGT) on subsequent risk of stroke. In 1986, 576 adults aged 25 years and older with impaired glucose tolerance in Da Qing, China, were randomly assigned by clinic to control, diet, exercise, or diet plus exercise intervention groups for a six-year period. Subsequently participants received medical care in their local clinics. We tracked participants for additional 17 years to ascertain stroke events and other outcomes. At the end of 23-year follow-up, 272 (50.2%) had progressed to diabetes, 169 (31.2%) regressed to normal glucose tolerance, and 101 (18.6%) remained impaired glucose tolerance. During the subsequent 17-year follow-up, 173 (31.9%) developed a stroke, 26.7% of normal glucose tolerances, 30.7% of impaired glucose tolerances, and 36.1% of those with diabetes. After controlling for age, sex, baseline blood pressure, smoking, total cholesterol, previous cardiovascular disease and intervention group, those who developed diabetes in the first six years had a higher incidence of stroke than those who reverted to normal glucose tolerance (HR = 1.49, 95% CI 1.01–2.19, p = 0.04), whereas for those who remained impaired glucose tolerance compared to those who regressed to normal glucose tolerance the HR was 1.25 (95% CI 0.80–1.93; p = 0.30). A 1-mmol/L increase in both fasting and 2-h post-load plasma glucose from entry to end of the six-year trial was significantly associated with a higher risk of development of stroke in the subsequent 17 years, respectively (HR = 1.07, 95% CI 1.03–1.11, p < 0.0001 for fasting glucose, HR = 1.05, 95% CI 1.02–1.09, p = 0.007 for 2-h post-load plasma glucose). Among Chinese adults with impaired glucose tolerance, early progression to diabetes predicted a higher risk of stroke, compared those who regressed to normal glucose tolerance.

    • 31 March 2009
      • Vol. 89  (12) , 851-4

    [The role of syntaxin1A/synaptosome-associated protein-25 in reversing hyperglycemia-induced alpha cell toxicity].

    by Xiao-Xia Shen, Hong-Liang Li, Jing Hong, Juan Xiao, Lin Pan, Guang-Wei Li

    To investigate the effects of reversal of hyperglycemic toxicity on the synthesis and secretion of glucagon by the alpha cells and the possible mechanisms thereof. Mouse glucagonoma cells of the line TC1-6 were cultured in medium containing 5.5 mmol/L glucose for 10 days (low glucose group, LG), in medium containing 25 mmol/L glucose for 10 days (high glucose group, HG), in medium with 25 mmol/L glucose for 5 days and then in medium with 5.5 mmol/L glucose for 5 days (high-low glucose group, HL group), or in medium with 5.5 mmol/L glucose for 5 days and then in medium with 25 mmol/L glucose for 5 days (LH group), Radioimmunoassay was used to detect the glucagon concentration in the supernatant. RT-PCR was used to detect the mRNA expression of glucagon in the TC1-6 cells. Western blotting was used to detect the protein expression of the Snare proteins: syntaxin1A and synaptosome-associated protein (SNAP)-25. (1) The glucagon level of the HG/LG group was lower than that of the HG group by 29% (P < 0.05). (2) The glucagon mRNA expression level in the TC1-6 cells of the HG/HL group was significantly lower than that of the HG group by (52.6 +/- 2.8)% (P < 0.05). (3) The syntaxin1A and SNAP-25 expression levels in the TC1-6 cells of the HG group were significantly higher than those of the LG group by 36% and 69% respectively (both P < 0.05), and the syntaxin1A and SNAP-25 expression levels in the TC1-6 cells of the HG/LG group were significantly lower than those of the HG group by 49% and 56% respectively (both P < 0.05). After removing the high glucose toxicity the abnormal glucagon secretion by the alpha-cells can be ameliorated obviously, and the expression levels of syntaxin1A and SNAP-25 proteins that promote the secretion of glucagon are reduced accordingly.